Elastic fibres are insoluble components of the extracellular matrix (ECM) of extensible connective tissues such as large arteries, skin, lungs, ligaments and auricular cartilage (Ref. 1). They endow these tissues with the mechanical properties necessary to withstand repeated cycles of stretch and recoil through life. They also influence the bioavailability of transforming growth factor β (TGFβ) family growth factors (Ref. 2) . Although fibrillin microfibrils arose in early metazoans (Refs 3, 4) ( Fig. 1 ), elastin and elastic fibres emerged only during vertebrate evolution as an essential requirement to reinforce high-pressure circulatory systems (Ref. 5) . Elastic fibres comprise an inner core of cross-linked elastin ensheathed within fibrillin microfibrils. These long-lasting structures begin to assemble during mid-gestation, with little adult elastic fibre assembly.
Mature elastic fibres have tissue-specific architectural arrangements that reflect different elastic requirements. Thus, arterial elastic fibres form concentric lamellar layers that support vascular elastic recoil. Dermal elasticity is based on integrated networks of thick reticular elastic fibres and thin fibres in the papillary dermis, and alveolar elastic fibres form fine networks that allow respiratory expansion and contraction (Ref. 1) .
Although tropoelastin and fibrillin are the two principal structural components of elastic fibres, several 'accessory' molecules contribute to 
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Expert Reviews in Molecular Medicine © 2013 Cambridge University Press Figure 1 . Evolutionary analysis of fibrillin. A list of species from the fibrillin (FBN) sequence alignment was generated, and used to create a common tree using the National Center for Biotechnology Information (NCBI) Taxonomy Browser. The resulting tree was imported into Cytoscape version 2.7, and generated using the organic layout. FBN types were identified using phylogenetic analysis and domain analysis of the FBN multiple sequence alignments and FBN types were mapped onto the common tree. Identified sequences were grouped into 5 categories: vertebrate FBNs 1-3, invertebrate FBN and fibrillin-like epidermal growth factor (EGF) array-containing proteins. The latter sequences had a high identity to FBN sequences but only contained EGF domains organised in arrays. Also indicated are the sequences, from the appearance of chordates that contain the arg-gly-asp (RGD) cell binding motif (branches shown in light brown). By comparison, branches shown in light purple precede chordates and RGD. The first emergence of other key extracellular proteins that interact with FBN is shown (dark blue arrows), along with the evolutionary timescale in million years ago (MYA).
elastic fibre assembly and function. From initial microfibril formation to the deposition and cross-linking of tropoelastin monomers upon microfibrils, these accessory proteins support the progression of elastic fibre formation in a spatially and temporally appropriate manner. For example, small fibulins influence the association of elastin with its cross-linking enzymes, thereby facilitating its stable deposition on microfibrils (see the Assembly of elastic fibres section).
Aberrant elastic fibre formation and/or altered homoeostasis cause many inherited and acquired diseases, with phenotypes ranging from mild (e.g. loose skin) to severe and potentially lifethreatening (e.g. vascular defects) (see the Elastic fibre disorders section). Heritable elastic fibre disorders include Marfan syndrome (MFS) caused by fibrillin-1 mutations (Ref. 6 ) and autosomal dominant cutis laxa (ADCL) caused by elastin mutations (Ref. 7) . Mutations in accessory glycoproteins such as fibulins-4 or -5 cause autosomal recessive cutis laxa (ARCL) (Ref. 8) , and in a disintegrin-like and metalloprotease (reprolysin-type) with thrombospondin-10 (ADAMTS-10) cause Weill-Marchesani syndrome (WMS) (Ref. 9) . Acquired elastic fibre disorders arise wherever elastic fibre structure and/or function are compromised; for example, actinic elastosis and vascular degeneration, as well as acquired forms of cutis laxa (CL) and pseudoxanthoma elasticum (PXE) .
In this review, we describe the current understanding of microfibril and elastic fibre composition and formation, delineate the diseases associated with elastic fibre defects and summarise the latest therapeutic advances.
Composition of elastic fibres
The structural and associated components of elastic fibres are outlined below; their roles in elastic fibre formation and function are further delineated below (see the Assembly of elastic fibres section).
Structural molecules Elastin
Elastin is the most abundant protein of elastic fibres, comprising approximately 90% of the mature structure. It is encoded by a gene on chromosome 7q11. 2 (Fig. 2 ). There is a unique proline-rich region in the N-terminal region of fibrillin-1, with corresponding regions of fibrillin-2 and fibrillin-3 being richer in glycine.
Fibrillin-1 (gene on chromosome 15q21.1) is the most abundant fibrillin isoform; it is expressed throughout life and is required for microfibril homoeostasis, whereas fibrillin-2 (gene on chromosome 5q23-q31) and fibrillin-3 (gene on chromosome 19p3) are expressed predominantly during development (Refs 17, 18, 19, 20) . Overlapping expression of fibrillins occurs in developing blood vessels, cartilage, bone and lungs, but tissue-specific differences are also apparent, e.g. fibrillin-1 in dermis, fibrillin-2 in peripheral nerves and fibrillin-3 in cartilage, perichondrium and developing bronchi (Ref. 20) . Fibrillin-2 may form the inner core of many fibrillin-1 containing microfibrils (Ref. 21) . Although rarely detected in adult skin, fibrillin-2 expression can increase during wound healing and in sclerosis (Ref. 22) . Mouse models confirm the critical importance of fibrillin-1 to vascular development and function. Fibrillin-1 null mice die perinatally from ruptured aortic aneurysm, whereas fibrillin-2 null mice have seemingly normal formation of the aorta, although doublenull mice have a much more severe aortic phenotype than fibrillin-1 null mice (Ref. 23 ). Both fibrillins thus perform partially overlapping functions during the development of the aorta and great arteries, with fibrillin-1 able to compensate for loss of fibrillin-2 but not vice versa. The fibrillin-3 gene is disrupted in rodents; so fibrillin-3 is not critical to all mammalian life (Ref. 19) .
Accessory molecules associated with microfibrils and elastic fibres
Many microfibril and elastic fibre-associated molecules have been identified by microscopy and immunochemical approaches (reviewed in Ref. 1; updated in Table 1 ). We summarise here selected molecules shown by functional analysis, mouse models and/or heritable diseases to contribute to elastic fibre formation and function; microfibril-associated molecules include the latent TGFβ binding proteins (LTBPs), ADAMTS isoforms and microfibrilassociated glycoprotein (MAGPs) and elastic fibre-associated molecules include the small fibulins 3-5 and lysyl oxidase (LOX). LTBPs: LTBPs 1-4 are large extracellular glycoproteins with a multi-domain structure that has similarities to the fibrillins, comprising cbEGF and TB domains, with an N-terminal cysteine-rich domain. They are expressed in many tissues including heart, placenta, lung, kidney, skeletal muscle and ovary and have cbEGF and TB domain homology with fibrillins (Refs 4, 54) (Fig. 2) . The third TB domain of LTBPs 1-4 can covalently bind the propeptide (latency-associated peptide, LAP) of the cytokine TGFβ (Refs 55, 56), which is rendered inactive when associated with its propeptide (forming the small latent complex). Association of this complex with LTBP forms the large latent complex, which can be sequestered within the ECM, thereby regulating TGFβ bioavailability (Refs 54, 55, 56 (Fig. 2) . The C-terminal (or ancillary) domain is variable between family members, although many contain multiple TSRs and may confer substrate-binding specificity, with the Nterminal domain providing catalytic activity. ADAMTS-10 lacks an optimal furin cleavage site (necessary for activation of ADAMTS enzymes) and is unlikely to be catalytically active in vivo. ADAMTSL family members, including those implicated in microfibril biology, contain multiple TSRs but lack disintegrin-like and catalytic domains. Thus, low/no catalytic activity is a hallmark of ADAMTS family members with identified roles in microfibril biology.
MAGPs: MAGP-1 (a ∼31 kDa glycoprotein) was originally detected in microfibril preparations from elastic and nonelastic tissues (Ref. 59) . It has an acidic N-terminal region enriched in proline and glutamine residues, and a cysteinerich C-terminal portion. It colocalises widely with microfibrils (Ref. 59) , and has been detected in purified microfibrils by mass spectrometry (Ref. 60) . Surprisingly, mice lacking the MAGP-1 gene show normal microfibrils and elastic fibre assembly (Refs 24, 61), so it is not essential for elastogenesis. Structurally related glycoprotein MAGP-2 (∼25 kDa) has a cysteine-rich central region, is rich in serine and threonine and binds integrins. It colocalises with microfibrils in some tissues LOX family: The five members of the LOX family (LOX, LOXL1-4) are secreted as zymogens, and are activated by removal of N-terminal propeptides by bone morphogenetic protein-1 (BMP-1) (Ref. 65) . LOX especially, but also its homologue LOXL1 catalyses the oxidative deamination of peptidyl lysine residues in elastin to generate α-aminoadipic-δ-semialdehydes that then spontaneously condense to form covalent desmosine and isodesmosine cross-links, and a very stable insoluble elastin core (Ref. 65 ). Their C-terminal regions show sequence homology but their N-terminal 'pro' regions vary greatly, and may impart specificity to the extracellular targeting of LOX enzymes.
Assembly of elastic fibres Microfibril formation
Assembly of fibrillin monomers into microfibrils is a complex process. 'Pro'fibrillin molecules are processed N-and C-terminally by furin/PACE proprotein convertases, either immediately before or upon secretion, thereby facilitating terminal interactions that enable linear and lateral multimerisation (Ref. 66) . Homotypic Nterminal interactions are enhanced by heparan sulphate (HS) (Ref. 67 ), whereas C-terminal interactions may underpin bead formation (Ref. 68) . In this way, microfibrils are thought to assemble at the cell surface (Fig. 3a) . Microfibril formation is unlikely to be solely a self-assembly process, and there is some evidence for cellular involvement. We reported that, in fibroblasts, microfibril deposition requires fibronectin arg-gly-asp (RGD)-dependent α5β1 integrins (Ref. 70) . Fibrillin-1 can also interact with cells through integrins α5β1 and αvβ3, and αvβ6 in epithelial cells (Refs 71, 72) . It remains to be determined whether direct fibrillin-1 interactions with cells are necessary for microfibril assembly and/or for specific tissue-specific functions of microfibrils (and elastic fibres) such as association with smooth muscle cells in the aorta.
Assembled microfibrils comprise fibrillin monomers aligned in a head-to-tail arrangement and laterally associated (probably eight molecules in cross-section) ( Refs 73, 74, 75) . 
Role for fibronectin
In mesenchymal cultures, fibronectin is an essential prerequisite for microfibril formation (Refs 26, 70, 79) . This relationship is surprising because fibrillin microfibrils arose in early metazoans and fibronectin-like molecules only in chordates (Refs 3, 4, 80). Fibronectin is able to bind several regions of fibrillin-1, as well as fibrillin multimers, whereas newly deposited microfibrils and fibronectin networks show initial colocalisation (Refs 70, 79, 81). It has been suggested that fibronectin could act as a template for microfibril deposition (Refs 70, 79); however fibrillin microfibrils occur in many lower organisms that lack fibronectin (Ref. 82) , and in fibronectin-null cultures (Ref. 83) , implying that fibronectin enhances rather than underpins microfibril assembly.
Role for HS
The glycosaminoglycan HS is strongly implicated in microfibril and elastic fibre assembly. It is a component of syndecan and glypican receptors, and of the basement membrane molecule perlecan. Supplementation of cell cultures with heparin effectively ablates microfibril assembly . Fibrillin molecules are secreted and, after processing N-and C-terminally by furin, interact homotypically at N-and C-termini leading to axial and lateral assembly to form microfibrils. Beads may arise from folding of terminal regions. Microfibrils may be stabilised by transglutaminase cross-links. The reason why fibronectin is needed for microfibril deposition is unclear, but it may act as a template for assembly and/or it may stimulate cytoskeletal tension through the α5β1 integrin, thereby facilitating assembly at fibrillar adhesions. Fibrillin-1 also interacts with α5β1, αvβ3 and αvβ6 integrins; however, it is not known whether these interactions are essential for microfibril assembly. 
Elastic fibre formation
Tropoelastin has the propensity to self-assemble through a process termed coacervation, which involves rapid molecular association, at increasing temperatures (Ref. 99) . Exposed hydrophobic domains interact in an entropically-driven process, resulting in lysine residues aligning in readiness for LOX-mediated cross-linking. In vitro, the sizes and properties of coacervation 'droplets', and the rate at which coacervation and maturation processes proceed, are dependent on tropoelastin concentration, pH, temperature and solution conditions In culture and tissues, elastin can self-associate pericellularly into globules that become crosslinked prior to deposition onto microfibrils (Refs 69, 102, 103) (Fig. 3b) . This initial stage in elastic fibre assembly, termed 'microassembly', may involve interaction of the C-terminal region of tropoelastin with α v β 3 integrin (Ref. 
Roles for fibulins
The homologous small fibulins (3) (4) (5) 
MFS and related pathologies
MFS (OMIM 154700) is the most prevalent fibrillinopathy, with an incidence of 2-3 per 10,000 people. A complex and phenotypically heterogeneous systemic disorder, MFS is characterised by severe cardiovascular, skeletal and ocular abnormalities, with symptoms ranging from isolated features through progressive classical MFS to severe early onset and rapidly progressive MFS (associated with early childhood mortality). Disease symptoms can reflect both elastic fibre deficiencies and perturbed TGFβ activity (Refs 6, 109). A lifethreatening complication of MFS is aortic rupture due to dilation of the ascending aorta.
Although commonly inherited as an autosomal dominant trait, 25% of cases arise from de novo Fibrillin-1 is highly susceptible to proteolytic degradation, and increased proteolytic susceptibility appears to play a significant role in the pathogenesis of MFS (Refs 6, 152, 153 ). Murine models of MFS (e.g. C1039 G heterozygote; Ref. 154 ) have revealed gross disruption to the elastic lamellar structure of the aorta (Fig. 4 fibrillin-1 fragments harbouring mutations associated with severe neonatal MFS showed enhanced susceptibility to physiological and non-physiological proteases. In addition, cathepsins K and V can cleave fibrillin-1 at multiple sites and thus may play a role in the pathogenesis of MFS (Ref. 152) .
TGFβ is known to control smooth muscle cell differentiation, matrix synthesis and vascular morphogenesis, and perturbed TGFβ signalling has been identified as a primary causative feature of MFS aortic disease progression (Refs 109, 157) (Fig. 4) . Mouse studies have shed further light on the complex contribution of TGFβ to disease progression. For example, mice with a fibrillin-1 deletion showed increased TGFβ activity in lung sections compared with wild-type littermates, coupled with impairment in alveolar septation (158) . Increased TGFβ activity also contributed to defective mitral valvulogenesis in a murine model of MFS. (Fig. 4) .
Enhanced TGFβ activity is associated with other fibrillinopathies including Stiff skin syndrome (Ref. MFS patients are routinely prescribed beta blockers to reduce haemodynamic stress on the aorta (Ref. 109) . In recent years, uncovering the link between increased TGFβ activity and MFS pathogenesis has led to the development of advanced therapeutic strategies that reduce TGFβ signalling. In particular, treatment with the angiotensin II type I receptor antagonist losartan was shown in MFS mice (Ref. 110 ) to prevent aortic aneurysm and to improve noncardiovascular symptoms (such as alveolar septation and muscle repair) (Fig. 5) . Several clinical trials have since been assessing the benefits of losartan treatment for MFS patients. In a clinical trial of patients with severe and rapidly progressive MFS, losartan treatment reduced both the rate of aortic root growth to 10% of pretreatment levels (Refs 109, 166) . A multicentre losartan trial is in progress (Ref. 
WMS and acromicric and GD
WMS is characterised by short stature, brachydactyly (short digits), eye abnormalities and joint stiffness. Both autosomal (WMS2; OMIM 608328) and recessive (WMS1; OMIM 277600) forms of WMS exist (Ref. 115) . Clinical manifestations of the acromicric (AD; OMIM 102370) and GD (OMIM 231050) include short stature, joint defects and thickened skin (Ref. 160) .
Mutations causing autosomal dominant WMS, AD and GD are located within the TB5 domain of fibrillin-1 (Refs 108, 157 ). This WMS-associated mutation abolishes binding of the TB5 domain to heparin, whereas six tested mutations associated with AD and GD reduce binding 
Elastinopathies
Mutations in elastin and elastic fibre-associated proteins cause disease through loss or gain of function, and increased susceptibility to inflammatory or proteolytic damage of elastic fibres (Refs 122, 123) .
Supravalvular aortic stenosis (SVAS; OMIM 185500) occurs in 1 in 20 000 live births, is inherited in an autosomal dominant manner but can also occur sporadically and is characterised by narrowing or obstruction of the ascending aorta. Other defects include obstruction of pulmonary, coronary, carotid and renal arteries. Severe SVAS may lead to dyspnoea, angina, systolic murmur, left ventricular hypertrophy ultimately leading to congestive heart failure. Although congenital non-syndromic forms of SVAS exist, SVAS is typically associated with Williams-Beuren syndrome (WBS), a complex developmental disorder (below). 
Acquired elastic fibre disorders
Acquired elastic fibre disorders arise wherever elastic fibre structure and function are compromised, including tissues such as skin, blood vessels and lungs. Some examples are highlighted below.
Acquired CL usually develops in adulthood. Characteristic secondary destruction of elastic fibres occurs because of dermal inflammation caused by other medical conditions or reactions to medicines. Systemic manifestations, which often lead to fatal outcomes, may include emphysema, hernias and vascular dilatation (Ref. 175) .
Marshall syndrome is a type of acquired CL typically affecting children after suffering neutrophilic dermatosis (Sweet's syndrome) (Ref. 176) .
Solar/actinic elastosis is a result of a prolonged exposure to sunlight, leading to degeneration of the elastic tissue of the dermis and consequently to premature ageing of the skin. Deposition of the elastotic material and decreased collagen synthesis lead to rough, inelastic, wrinkled and hyperpigmented skin. Current therapy of choice is a skinrejuvenating photodynamic therapy in which photosensitisers and diverse light sources have been successfully used to reverse the effects of photodamage (Ref. 177) .
Acquired PXE is characterised by cutaneous mineralisation and fragmentation of elastic fibres leading to lax inelastic skin. Unlike the heritable PXE, the acquired PXE is non-systemic and is limited to the skin only. Exposure to chemicals such as calcium-ammonium-nitrate salts, mechanical stress and abnormal calcium-phosphate metabolism has been implicated in the development of this disease (Ref. 178 ). There are no generally accepted therapies for the acquired PXE. Papillary dermal elastolysis is a rare condition, similar to PXE, which usually affects elderly women, and is associated with elastolytic papules on the neck and supraclavicular sites (Ref. 179) .
Ageing changes to blood vessels and lungs: loss of elastic fibre integrity and elastic recoil are common features of ageing changes to blood vessels especially the elastic arteries, whereas pulmonary emphysema is associated with loss of elasticity and pathological alveolar remodelling (Ref. Elastosis perforans serpiginosa (EPS; OMIM 130100) is a rare degenerative skin disease, which exhibits loss of elastic fibres in the upper dermis, following extended treatment with Dpenicillamine that chelates copper and inhibits cross-linking of elastin by copper-dependent lysyl oxidase (Ref. 184 ).
Research in progress and outstanding research questions
Recent progress in treating MFS and related diseases with losartan and other therapies that target TGFβ activity have led to improved patient outcomes. However, further understanding of the biology of elastic fibres and their assembly is urgently needed to advance the therapeutic prospects for elastic fibre diseases. Current research on elastic fibres aims to define how cells and their integrin and heparan sulphate proteoglycans (HSPG) receptors direct the assembly of microfibrils and elastic fibres, how fibronectin and the ADAMTS and ADAMTSL molecules influence microfibril deposition and how pericellular processing (by furin/PACE enzymes) and cross-linking (by LOX and tissue transglutaminase enzymes) regulate elastic fibre deposition. New insights into how LTBPs are deposited in the matrix, and how active TGFβ and BMPs are released from these complexes are needed to resolve precisely how TGFβ growth factor bioavailability is controlled. All this information is critical for elucidating how defects in microfibrils and elastic fibres cause distinct genetic and acquired diseases by perturbing different stages in their assembly, their structural integrity or their susceptibity to proteolytic attack. We also need to understand much better how inflammatory enzymes cause elastic fibre remodelling and loss of both microfibril and elastic fibre functional integrity in disease and ageing. There is a need to identify biomarkers of elastic fibre damage to enable early diagnosis and treatment. Much recent progress has been made in the engineering of vascular constructs based on elastin and elastic fibre components, and this approach offers great promise for the repair of damaged elastic tissues. Such advances will provide mechanistic targets to prevent elastic fibre degeneration and to encourage de novo elastic fibre formation in regenerating tissues. Features associated with this article (continued) Figure 5 . Prevention of aortic aneurysm in mice by losartan. Tables  Table 1. Microfibril and elastic fibre-associated molecules (updated from Ref. 1). 
